Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Humacyte, Inc. (NASDAQ:HUMA) has received a consensus rating of “Moderate Buy” from the eight analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $8.1429.

A number of brokerages have recently weighed in on HUMA. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of Humacyte in a research note on Monday, December 1st. Wall Street Zen cut Humacyte from a “hold” rating to a “sell” rating in a report on Sunday, December 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Humacyte in a research report on Monday, December 29th. Finally, UBS Group reaffirmed a “buy” rating on shares of Humacyte in a research note on Monday, December 1st.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. R Squared Ltd acquired a new position in Humacyte during the fourth quarter worth about $25,000. Atom Investors LP acquired a new stake in Humacyte in the 4th quarter valued at about $25,000. Truist Financial Corp bought a new position in shares of Humacyte during the 3rd quarter valued at about $28,000. Prudential Financial Inc. bought a new position in shares of Humacyte during the 2nd quarter valued at about $28,000. Finally, Financial Advisors Network Inc. acquired a new position in shares of Humacyte in the 2nd quarter worth approximately $28,000. Institutional investors own 44.71% of the company’s stock.

Humacyte Stock Performance

HUMA stock opened at $0.78 on Friday. The company has a market capitalization of $146.61 million, a P/E ratio of -3.40 and a beta of 1.89. The company has a quick ratio of 0.90, a current ratio of 1.62 and a debt-to-equity ratio of 2.97. The company has a 50-day simple moving average of $1.08 and a 200 day simple moving average of $1.30. Humacyte has a fifty-two week low of $0.70 and a fifty-two week high of $3.36.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.